{
  "report_rows": [
    {
      "kpi": "Fiscal Q3 diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$1.42 vs. cons $1.36",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Fiscal Q3 operating revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$945M vs. cons $938.5M",
      "confidence": "LOW"
    },
    {
      "kpi": "Nine-month capital expenditures",
      "prediction": "BEAT",
      "answer": "pred ~$3.15B vs. cons $3.10B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Fiscal 2026 diluted EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$8.45-$8.55, midpoint $8.50 vs. cons $8.44 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Capital-expenditure guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$4.20B vs. cons $4.20B (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "Texas Rule 7.7102 pretax benefit",
      "prediction": "UNCHANGED",
      "answer": "guide ~$160M midpoint vs. cons $160M (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "O&M expense guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$875M midpoint vs. cons $875M (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 1.4,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.5,
  "day5_path": "FADE",
  "day5_rationale": "A roughly 4.4% Q3 EPS beat and a ~$0.05 midpoint guidance increase should initially support the shares, but implied fiscal Q4 EPS of ~$1.16 versus consensus near $1.16 leaves little room for upward out-period revisions; therefore, the predicted +1.4% day-1 residual fades to +0.5% cumulatively by day 5.",
  "day5_confidence": "MEDIUM"
}